Open Access Articles- Top Results for Nelivaptan


Systematic (IUPAC) name
Clinical data
439687-69-1 7pxN
PubChem CID 9895468
IUPHAR ligand 2202
ChemSpider 8071134 7pxY
ChEMBL CHEMBL582857 7pxY
Chemical data
Formula C30H32ClN3O8S
630.11 g/mol
 14pxN (what is this?)  (verify)

Nelivaptan (INN[1]), codenamed SSR-149,415, is a selective and orally active non-peptide vasopressin receptor antagonist selective for the V1b subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]


  1. ^ World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information 21 (4): 341. 
  2. ^ Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. PMC 122955. PMID 11959912. doi:10.1073/pnas.092012099. 
  3. ^ Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS Drug Reviews 11 (1): 53–68. PMID 15867952. doi:10.1111/j.1527-3458.2005.tb00035.x. 
  4. ^ "Second-quarter 2008 results" (PDF). Press Release. Sanofi-Aventis. 2008-07-31. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist). 

External links

Lua error in package.lua at line 80: module 'Module:Buffer' not found.